Barinthus Biotherapeutics (BRNS) Stock Price, News & Analysis

Company Overview

Barinthus Biotherapeutics plc (NASDAQ:BRNS) is a clinical-stage biopharmaceutical company developing T-cell immunotherapies designed to treat autoimmune diseases. Its approach is intended to selectively modulate disease-causing immune responses while preserving broader immune-system function.

The company’s pipeline includes VTP-1000, an investigational therapy being developed for celiac disease. Barinthus is also advancing additional preclinical and clinical programs that use its proprietary immune-modulation technologies to target other autoimmune conditions. The company’s development strategy focuses on antigen-specific tolerance, which aims to reduce harmful immune reactions against particular tissues or proteins.

Barinthus Biotherapeutics was formerly known as Vaccitech plc and adopted its current name in 2024 as it sharpened its focus on autoimmune disease. The company is headquartered in the United Kingdom and operates as an international biotechnology business serving global healthcare and pharmaceutical markets. William Enright serves as chief executive officer.

Key Stats

• Today's Range: $0.74 to $0.74
• 50-Day Range: $0.56 to $0.78
• 52-Week Range: $0.51 to $1.83
• Volume: N/A
• Average Volume: 83,130 shs
• Market Capitalization: $30.23 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.00
• Consensus Rating: Hold

Barinthus Biotherapeutics Stock Analysis - MarketRank™

Barinthus Biotherapeutics scored higher than 35% of companies evaluated by MarketBeat, and ranked 710th out of 884 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Hold

Consensus Rating

Barinthus Biotherapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.

Upside Potential

Barinthus Biotherapeutics has a consensus price target of $4.00, representing about 440.5% upside from its current price of $0.74.

Amount of Analyst Coverage

Barinthus Biotherapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Barinthus Biotherapeutics are expected to decrease in the coming year, from ($0.93) to ($1.07) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Barinthus Biotherapeutics is -0.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Barinthus Biotherapeutics is -0.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Barinthus Biotherapeutics has a P/B Ratio of 0.41. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.04% of the float of Barinthus Biotherapeutics has been sold short.

Short Interest Ratio / Days to Cover

Barinthus Biotherapeutics has a short interest ratio ("days to cover") of 0.26, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Barinthus Biotherapeutics has recently increased by 46.19%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Barinthus Biotherapeutics does not currently pay a dividend.

Dividend Growth

Barinthus Biotherapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 1 people have searched for BRNS on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 0.6 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Barinthus Biotherapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

8.50% of the stock of Barinthus Biotherapeutics is held by insiders.

Percentage Held by Institutions

25.20% of the stock of Barinthus Biotherapeutics is held by institutions.

Company Calendar

• Last Earnings: 8/07/2026
• Today: 10/08/2026
• Next Earnings (Estimated): 11/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:BRNS
• Previous Symbol: NASDAQ:BRNS
• CIK: 1828185
• Web: www.barinthusbio.com
• Phone: 44-1865-818-808
• Fax: N/A
• Employees: 107
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Barinthus Biotherapeutics: $4.00
• High Price Target: $4.00
• Low Price Target: $4.00
• Potential Upside/Downside: +440.5%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.03)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$66.43 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -59.15%
• Return on Assets: -43.80%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.54
• Quick Ratio: 5.54

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.82 per share
• Price / Book: 0.41

Miscellaneous

• Outstanding Shares: 40,849,000
• Free Float: 37,377,000
• Market Cap: $30.23 million
• Optionable: N/A
• Beta: -0.37